Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 10/20 | 0.72 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.72 |
| ▸ | USP47 | Q96K76 | 6/20 | 0.71 |
| ▸ | USP10 | Q14694 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPD | P32754 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680054 | 0.89 | USP7 (0.67) | USP7PADI4USP47USP10MAPT | |
| SCHEMBL2682523 | 0.87 | USP47 (0.70) | USP7PADI4USP47USP10MAPT | |
| SCHEMBL2680315 | 0.85 | USP7 (0.79) | USP7PADI4USP47USP10PDE7A | |
| SCHEMBL2681089 | 0.84 | USP7 (0.77) | USP7PADI4USP47USP10PDE7A | |
| SCHEMBL29279218 | 0.84 | USP47 (0.76) | USP7PADI4USP47USP10PDE7A | |
| SCHEMBL2681075 | 0.84 | USP7 (1.00) | USP7PADI4USP47USP10PDE7A | |
| SCHEMBL27139432 | 0.81 | USP7 (0.73) | USP7PADI4USP47USP10MAPT | |
| SCHEMBL2681880 | 0.81 | USP47 (0.85) | USP7PADI4USP47USP10MAPT | |
| SCHEMBL2680611 | 0.80 | USP7 (0.71) | USP7PADI4USP47USP10MAPT | |
| SCHEMBL2680932 | 0.79 | USP47 (0.77) | USP7PADI4USP47USP10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | USP7 437/4885PADI4 4342/4885USP47 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.